Compare FOA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FOA | SGMT |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | 784 | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.1M | 169.4M |
| IPO Year | N/A | 2021 |
| Metric | FOA | SGMT |
|---|---|---|
| Price | $19.70 | $6.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $26.00 | ★ $26.13 |
| AVG Volume (30 Days) | 46.7K | ★ 742.9K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $0.58 | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.77 | $4.50 |
| 52 Week High | $29.58 | $11.41 |
| Indicator | FOA | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 46.60 |
| Support Level | $19.00 | $6.33 |
| Resistance Level | $20.17 | $7.39 |
| Average True Range (ATR) | 0.80 | 0.39 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 67.37 | 33.91 |
Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.